Solid BiosciencesSLDB
SLDB
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,279% more call options, than puts
Call options by funds: $2.38M | Put options by funds: $100K
75% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 20
1.97% less ownership
Funds ownership: 92.89% [Q3] → 90.92% (-1.97%) [Q4]
2% less funds holding
Funds holding: 92 [Q3] → 90 (-2) [Q4]
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
42% less capital invested
Capital invested by funds: $250M [Q3] → $145M (-$105M) [Q4]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
220%
upside
Avg. target
$15.60
353%
upside
High target
$20
481%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
JP Morgan Anupam Rama 24% 1-year accuracy 15 / 62 met price target | 220%upside $11 | Overweight Maintained | 13 Mar 2025 |
HC Wainwright & Co. Arthur He 16% 1-year accuracy 5 / 32 met price target | 481%upside $20 | Buy Maintained | 10 Mar 2025 |
Chardan Capital Geulah Livshits 10% 1-year accuracy 6 / 58 met price target | 365%upside $16 | Buy Maintained | 7 Mar 2025 |
Citizens Capital Markets Silvan Tuerkcan 19% 1-year accuracy 10 / 53 met price target | 336%upside $15 | Market Outperform Reiterated | 7 Mar 2025 |
Truist Securities Joon Lee 54% 1-year accuracy 22 / 41 met price target | 365%upside $16 | Buy Initiated | 8 Jan 2025 |
Financial journalist opinion
Based on 8 articles about SLDB published over the past 30 days
Neutral
GlobeNewsWire
12 hours ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 43,374 restricted stock units (“RSUs”) to three newly hired employees.
Negative
New York Post
1 day ago
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Neutral
GlobeNewsWire
2 weeks ago
Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
CHARLESTOWN, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy (Duchenne), at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place in Dallas, TX, March 16-19, 2025.
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts Believe Solid Biosciences (SLDB) Could Rally 198.18%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 198.2% in Solid Biosciences (SLDB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
3 weeks ago
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
Solid Biosciences stock soars 60% in a month after the company announced positive initial data from its phase I/II DMD study of SGT-003.
Neutral
GlobeNewsWire
3 weeks ago
Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Duchenne : Reported positive initial data from INSPIRE DUCHENNE trial of next-generation Duchenne gene therapy candidate, SGT-003; In mid-2025, Company plans to request a U.S. Food and Drug Administration (FDA) meeting to discuss potential accelerated approval pathways -
Neutral
GlobeNewsWire
3 weeks ago
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:
Neutral
GlobeNewsWire
4 weeks ago
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 11,950 restricted stock units (“RSUs”) to one newly hired employee.
Positive
MarketBeat
1 month ago
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences NASDAQ: SLDB skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%.
Positive
Benzinga
1 month ago
Solid Biosciences Stock Surges On Upbeat Duchenne Muscular Dystrophy Gene Therapy Data
On Tuesday, Solid Biosciences Inc. SLDB released initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy product candidate intended for the treatment of Duchenne muscular dystrophy.
Charts implemented using Lightweight Charts™